This pipeline uses various statistical tests to identify genes whose promoter methylation levels correlated to selected clinical features.
Testing the association between 20232 genes and 8 clinical features across 79 samples, statistically thresholded by Q value < 0.05, 5 clinical features related to at least one genes.
-
51 genes correlated to 'Time to Death'.
-
KCNF1 , PER1 , ECE2 , FBLN5 , KCNK13 , ...
-
320 genes correlated to 'PATHOLOGY.T'.
-
PAX6 , TRH , ALX3 , TLX3 , OTP , ...
-
1 gene correlated to 'PATHOLOGY.N'.
-
HMX3
-
136 genes correlated to 'PATHOLOGICSPREAD(M)'.
-
HSD3B2 , LOC100132247 , KRAS , ERCC2 , PRR24 , ...
-
384 genes correlated to 'TUMOR.STAGE'.
-
PAX6 , GATA4 , NKX2-6 , TLX3 , OTP , ...
-
No genes correlated to 'AGE', 'GENDER', and 'KARNOFSKY.PERFORMANCE.SCORE'.
Complete statistical result table is provided in Supplement Table 1
Clinical feature | Statistical test | Significant genes | Associated with | Associated with | ||
---|---|---|---|---|---|---|
Time to Death | Cox regression test | N=51 | shorter survival | N=51 | longer survival | N=0 |
AGE | Spearman correlation test | N=0 | ||||
GENDER | t test | N=0 | ||||
KARNOFSKY PERFORMANCE SCORE | Spearman correlation test | N=0 | ||||
PATHOLOGY T | Spearman correlation test | N=320 | higher pT | N=306 | lower pT | N=14 |
PATHOLOGY N | Spearman correlation test | N=1 | higher pN | N=1 | lower pN | N=0 |
PATHOLOGICSPREAD(M) | ANOVA test | N=136 | ||||
TUMOR STAGE | Spearman correlation test | N=384 | higher stage | N=379 | lower stage | N=5 |
Time to Death | Duration (Months) | 0-182.7 (median=20.9) |
censored | N = 60 | |
death | N = 12 | |
Significant markers | N = 51 | |
associated with shorter survival | 51 | |
associated with longer survival | 0 |
HazardRatio | Wald_P | Q | C_index | |
---|---|---|---|---|
KCNF1 | 6401 | 8.158e-08 | 0.0017 | 0.82 |
PER1 | 4501 | 1.13e-07 | 0.0023 | 0.785 |
ECE2 | 3801 | 1.478e-07 | 0.003 | 0.867 |
FBLN5 | 1301 | 1.749e-07 | 0.0035 | 0.719 |
KCNK13 | 7601 | 1.877e-07 | 0.0038 | 0.775 |
PTCH1 | 17001 | 2.101e-07 | 0.0043 | 0.862 |
IGF2AS | 1801 | 3.265e-07 | 0.0066 | 0.899 |
SORBS3 | 1301 | 3.62e-07 | 0.0073 | 0.768 |
NRARP | 6001 | 3.881e-07 | 0.0078 | 0.709 |
DDN | 1101 | 3.942e-07 | 0.008 | 0.63 |
AGE | Mean (SD) | 60.51 (12) |
Significant markers | N = 0 |
GENDER | Labels | N |
FEMALE | 24 | |
MALE | 55 | |
Significant markers | N = 0 |
No gene related to 'KARNOFSKY.PERFORMANCE.SCORE'.
KARNOFSKY.PERFORMANCE.SCORE | Mean (SD) | 92.11 (14) |
Score | N | |
40 | 1 | |
90 | 9 | |
100 | 9 | |
Significant markers | N = 0 |
PATHOLOGY.T | Mean (SD) | 1.78 (0.98) |
N | ||
T1 | 47 | |
T2 | 3 | |
T3 | 28 | |
T4 | 1 | |
Significant markers | N = 320 | |
pos. correlated | 306 | |
neg. correlated | 14 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
PAX6 | 0.7441 | 3.91e-15 | 7.91e-11 |
TRH | 0.7168 | 1.097e-13 | 2.22e-09 |
ALX3 | 0.7107 | 2.192e-13 | 4.43e-09 |
TLX3 | 0.6993 | 7.603e-13 | 1.54e-08 |
OTP | 0.695 | 1.198e-12 | 2.42e-08 |
EVX2 | 0.6759 | 8.24e-12 | 1.67e-07 |
NR5A2 | 0.6751 | 8.872e-12 | 1.79e-07 |
PHOX2B | 0.6751 | 8.884e-12 | 1.8e-07 |
NKX2-6 | 0.6683 | 1.714e-11 | 3.47e-07 |
PPP1R16B | 0.6671 | 1.906e-11 | 3.85e-07 |
PATHOLOGY.N | Mean (SD) | 0.52 (0.72) |
N | ||
N0 | 19 | |
N1 | 8 | |
N2 | 4 | |
Significant markers | N = 1 | |
pos. correlated | 1 | |
neg. correlated | 0 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
HMX3 | 0.7418 | 1.793e-06 | 0.0363 |
PATHOLOGICSPREAD(M) | Labels | N |
M0 | 45 | |
M1 | 4 | |
MX | 27 | |
Significant markers | N = 136 |
ANOVA_P | Q | |
---|---|---|
HSD3B2 | 8.765e-15 | 1.77e-10 |
LOC100132247 | 8.163e-12 | 1.65e-07 |
KRAS | 2.545e-11 | 5.15e-07 |
ERCC2 | 2.943e-11 | 5.95e-07 |
PRR24 | 5.299e-11 | 1.07e-06 |
RNASE4 | 5.624e-11 | 1.14e-06 |
SPC24 | 6.758e-11 | 1.37e-06 |
ANG | 7.035e-11 | 1.42e-06 |
SLC26A2 | 8.433e-11 | 1.71e-06 |
TMEM25 | 2.659e-10 | 5.38e-06 |
TUMOR.STAGE | Mean (SD) | 1.91 (1.1) |
N | ||
Stage 1 | 44 | |
Stage 2 | 3 | |
Stage 3 | 21 | |
Stage 4 | 8 | |
Significant markers | N = 384 | |
pos. correlated | 379 | |
neg. correlated | 5 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
PAX6 | 0.7403 | 2.147e-14 | 4.34e-10 |
GATA4 | 0.7224 | 1.752e-13 | 3.54e-09 |
NKX2-6 | 0.7016 | 1.668e-12 | 3.38e-08 |
TLX3 | 0.7003 | 1.908e-12 | 3.86e-08 |
OTP | 0.6911 | 4.869e-12 | 9.85e-08 |
TRH | 0.6894 | 5.752e-12 | 1.16e-07 |
FOXE1 | 0.68 | 1.427e-11 | 2.89e-07 |
NKX2-5 | 0.6785 | 1.649e-11 | 3.34e-07 |
NHLH2 | 0.6763 | 2.021e-11 | 4.09e-07 |
PRDM13 | 0.6761 | 2.056e-11 | 4.16e-07 |
-
Expresson data file = KIRP.meth.for_correlation.filtered_data.txt
-
Clinical data file = KIRP.clin.merged.picked.txt
-
Number of patients = 79
-
Number of genes = 20232
-
Number of clinical features = 8
For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels
For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R
For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R
For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.